USA Sign Frame and Stake Introduces Biobased, Biodegradable Landscape Stakes Made from Verde Bioresins' PolyEarthylene(R)

September 18, 2025 6:00 AM

Verde Bioresins® ("Verde"), a leading producer of renewable and sustainable bioplastics, announced its partnership with USA Sign Frame and Stake, parent company of the StakeDriver™ brand of professional-grade residential, construction, and industrial landscape products. Powered by Verde's patented PolyEarthylene® biopolymer technology, Stake Driver's stakes are a breakthrough line of biobased and biodegradable landscape stakes-delivering the...

Read more

Alligator Bioscience AB Announces Final Outcome of Exercise of Warrants Series TO 13

September 17, 2025 9:15 AM

Alligator Bioscience (STO:ATORX)NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES.The exercise period for warrants...

Read more

uBriGene Unveils V2.0 RNA-LNP iPSC Reprogramming Kit Optimized for PBMCs and Hard-to-Reprogram Cells

September 17, 2025 7:00 AM

uBriGene Biosciences, a leader in CGT CDMO and iPSC manufacturing technology development, today announced the launch of its 2nd-Generation iPSC Reprogramming Kit, powered by proprietary RNA-LNP technology. The kit is designed and proven to deliver best-in-class performance to reprogram peripheral blood mononuclear cells (PBMCs) to induced pluripotent stem cell (iPSC).Key Advantages of the 2nd-Generation RNA-LNP Reprogramming Kit:RNA-LNP Based,...

Read more

AbTherx and Mosaic Biosciences Forge Exclusive Partnership to Provide Milestone and Royalty-Free Access to AbTherx's Premier Human Antibody Discovery Technology

September 17, 2025 6:00 AM

AbTherx and Mosaic Biosciences today announced a strategic agreement under which Mosaic will be the exclusive provider of antibody discovery services using AbTherx's Atlas Full Human Diversity (FHD) Transgenic Mouse. The collaboration establishes a unified pathway for biotech and biopharma partners to launch discovery campaigns powered by the FHD platform, with Mosaic providing a seamless, end-to-end experience from immunization through...

Read more

LIXTE's Bold Blueprint to Rewire Cancer's Master Switch and Redefine Its Own Future (NASDAQ: LIXT)

September 16, 2025 8:30 AM

For a small-cap biotech, the headlines often center on fundraising, partnerships, or meeting exchange requirements. But every so often, the spotlight shifts to the science itself. Especially when it's the kind with the potential to rewrite how cancer is treated. That is where LIXTE Biotechnology Holdings (NASDAQ:LIXT) finds itself today.Earlier this month, the company put the focus squarely on its lead compound, LB-100. It is the only...

Read more

Longwood Healthcare Leaders to Host Boston CEO, Off-the-Record Networking and Discussion Forum, Convening Life Science Thought Leaders

September 16, 2025 7:00 AM

Longwood Healthcare Leaders will convene top biopharmaceutical executives for two days of discussion and networking at Boston CEO, held at the Mandarin Oriental Hotel, Boston, on October 27-28, 2025. The leading industry meeting is co-hosted with distinguished leaders in the industry including Marc Casper (CEO, Thermo Fisher Scientific), Thomas Schinecker (CEO, Roche), Bob Langer (Institute Professor, MIT; Co-Founder, Moderna), Phil Sharp...

Read more

Alligator Bioscience AB Announces Preliminary Outcome of Exercise of Warrants Series TO 13

September 16, 2025 6:05 AM

Alligator Bioscience (STO:ATORX)NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES.The exercise period for warrants...

Read more

FluoGuide Receives Positive FDA Feedback on FG001 in High-Grade Glioma

September 16, 2025 5:20 AM

FluoGuide A/S ("FluoGuide" or the "Company") received positive feedback and alignment with the FDA at a pre-IND consultation on its U.S. clinical study design. This supports both the upcoming IND submission and a future NDA filing for FG001, an intraoperative imaging agent for high-grade glioma (HGG).FluoGuide has achieved several important milestones in 2025. Our comprehensive pre-IND package included detailed information on completed...

Read more

LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ:LIXT)

September 15, 2025 5:40 PM

For most small-cap biotechs, the summer months mean quiet trial work and the occasional conference slide deck. LIXTE Biotechnology Holdings (NASDAQ:LIXT) had other plans. Since June 2025, the company has rewritten its playbook, refreshing leadership, raising capital, securing scientific validation, and even moving part of its treasury into digital assets. If LB-100 is the scientific spark, then the corporate fire LIXTE is lighting around it may...

Read more

enVVeno Medical Updates Regulatory Status of VenoValve(R)

September 15, 2025 8:45 AM

enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it will file a request for supervisory appeal of the not-approvable letter from the Center for Devices and Radiological Health (CDRH) of the U.S. Food & Drug Administration (FDA) received on August 19, 2025, in response to its Premarket Approval (PMA) application for the...

Read more

Vicore to Present at Pareto Securities' 16th Annual Healthcare Conference

September 15, 2025 2:20 AM

Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation at Pareto Securities' 16th Annual Healthcare Conference 2025:Location: Stockholm, SwedenFormat: Presentation and 1×1 meetingsPresentation Date and Time: Tuesday, September 16 at 3:45 PM CESTParticipants: Hans Jeppsson, CFO, and Bertil Lindmark, CMOThe company's management will...

Read more

CORRECTION FROM SOURCE: Faron Pharmaceuticals Ltd: Half-Year Financial Results 1 January - 30 June 2025

September 12, 2025 12:00 PM

Faron Pharmaceuticals Ltd (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, has published its unaudited half-year financial results for the six months ended 30 June 2025, on 27 August 2025.Figures in parentheses refer to the corresponding period of previous year, unless otherwise...

Read more

Canyon Labs Elevates Leadership to Unite Sites and Strengthen Client Partnerships

September 12, 2025 8:00 AM

Canyon Labs announced today the promotion of Sarah Ptach to President and Chief Executive Officer and David Kudla to Chief Operating Officer, reinforcing the company's vision of building a unified organization that delivers seamless solutions for clients across all locations.As a contract testing and consulting partner to the medical device and pharmaceutical industries, Canyon Labs is committed to more than transactional services. The company...

Read more

Alligator to Present New Preclinical Results on ATOR-4066 at CICON25

September 12, 2025 3:05 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, announced that new preclinical results on its bispecific antibody ATOR-4066 will be presented today at the 9th International Cancer Immunotherapy Conference (CICON25), jointly organized in Utrecht, by the Cancer Research Institute (CRI), the European Network for Cancer Immunotherapy (ENCI), and other...

Read more

PharmaNest, NIH and VCU Launch Confirmatory Retrospective Outcome Study With 1,765 Patients to Advance AI-Driven Digital Pathology in MASLD

September 11, 2025 5:00 PM

PharmaNest Inc. announced today a multi-institutional research collaboration with Virginia Commonwealth University (VCU) and the National Institutes of Health (NIH) to confirm the prognostic performance of artificial intelligence (AI) powered digital pathology biomarkers in metabolic dysfunction-associated steatotic liver disease (MASLD) in a retrospective cohort of 1,765 patients with MASH (NASH CRN DB2 Cohort).The collaboration unites...

Read more

Protalix BioTherapeutics to Present at Investor Summit Virtual

September 11, 2025 10:55 AM

Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that Eyal Rubin, the Company's former Sr. Vice President and Chief Financial Officer, will present at the Investor Summit Virtual on September 16, 2025, updating investors...

Read more

Imagene AI and Sheba Medical Center Launch a Precision Oncology Intelligence Alliance to Scale Personalized Cancer Care

September 11, 2025 8:00 AM

Imagene AI, a pioneer in multimodal foundation models for precision medicine, and ARC, the innovation arm of Sheba Medical Center, a global beacon of medical innovation and research ranked a top-ten world hospital by Newsweek, today announced an expanded strategic collaboration to advance cancer research and care with real-world data and multimodal AI.Initially applied in lung cancer care at Sheba, where Imagene AI's multi-gene NSCLC application...

Read more

Moolec Science Secures Regulatory Approval for Safflower GLASO Technology in Argentina, Expands U.S. Acreage, and Strengthens Leadership With CFO Appointment

September 11, 2025 7:00 AM

Moolec Science Limited, a wholly-owned subsidiary of Moolec Science SA (NASDAQ:MLEC)("the Company"; "Moolec"), an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food industry, today announced regulatory approval in Argentina for its safflower GLASO[1] technology, the expansion of U.S. acreage to support revenue-generating activities, and the appointment of a new Chief Financial...

Read more

Lunai Bioworks subsidiary BioSymetrics and Brigham and Women’s Hospital Awarded NIH STTR Grant to Develop AI-Powered Platform for Alcohol Use Disorder Therapeutics

September 11, 2025 7:00 AM

Lunai Bioworks Inc.'s (NASDAQ:RENB) wholly-owned subsidiary BioSymetrics Inc. today announced the award of a prestigious Small Business Technology Transfer (STTR) grant from the National Institutes of Health (NIH). The funding, awarded jointly to BioSymetrics and Brigham and Women's Hospital, will support the development of a novel platform that combines artificial intelligence and in vivo zebrafish screening to accelerate drug discovery for...

Read more

Last Day of Trading in Warrants Series TO 13 in Alligator Bioscience is 11 September 2025

September 11, 2025 2:50 AM

Alligator Bioscience (STO:ATORX)NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.11 September 2025 is the last day of trading in warrants...

Read more